Member access

4-Traders Homepage  >  Shares  >  Euronext Alternext  >  Neovacs    ALNEV   FR0004032746

NEOVACS (ALNEV)

365
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
03/24/2015 03/25/2015 03/26/2015 03/27/2015 03/30/2015 Date
1.07(c) 1.06(c) 1.03(c) 0.98(c) 1.02 Last
115 217 82 648 331 626 510 773 330 347 Volume
-1.83% -0.93% -2.83% -4.85% +4.08% Change
More quotes
Financials (€)
Sales 2014 0,03 M
EBIT 2014 -8,20 M
Net income 2014 -7,21 M
Debt 2014 2,79 M
Yield 2014 -
Sales 2015 5,03 M
EBIT 2015 -4,83 M
Net income 2015 -6,33 M
Debt 2015 1,39 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 1 014x
EV / Sales 2015 4,76x
Capitalization 22,5 M
More Financials
Company
Neovacs SA is a biotechnology company.It focuses on an active immunotherapy technology platform with applications in the treatment of autoimmune and inflammatory diseases and cancer.It focuses on development on two Kinoids: Tumor Necrosis Factor-Kinoid and Interferon-Kinoid.The Tumor Necrosis... 
More about the company
Surperformance© ratings of Neovacs
Trading Rating : Investor Rating :
More Ratings
Latest news on NEOVACS
03/23 NEOVACS : Strengthens North American Presence With Formation of U.S. Subsidiary
03/23 NEOVACS : STRENGTHENS NORTH AMERICAN PRESENCE WITH FORMATION OF U.S. SUBSIDIARY ..
03/23 NEOVACS : Strengthens north american presence with formation of u.s. subsidiary
03/22 NEOVACS : strengthens american presence with formation of U.S. subsidiary
03/11 NEOVACS : Strengthens Scientific Leadership Through Executive Appointments
03/11 NEOVACS : STRENGTHENS SCIENTIFIC LEADERSHIP THROUGH EXECUTIVE APPOINTMENTS (DGAP..
03/11 NEOVACS : strengthens scientific leadership through executive appointments
03/11 NEOVACS : STRENGTHENS SCIENTIFIC LEADERSHIP THROUGH EXECUTIVE APPOINTMENTS (DGAP..
More news
Sector news : Biotechnology & Medical Research - NEC
01:18p PUMA BIOTECHNOLOGY : NYSE stocks posting largest percentage increases
03/27 ISIS PHARMACEUTICALS : Earnings Coverage - Isis Pharma
03/26 Alliance invokes Elliott track record in appeal against board shake-up
More sector news : Biotechnology & Medical Research - NEC


Comments 
Advertisement
Chart NEOVACS
Duration : Period :
Neovacs Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF